# Michael Michael

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-michael/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,292 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 45 |
| i10-index | 106 |
| Last Known Institution | Peter MacCallum Cancer Centre |
| OpenAlex ID | https://openalex.org/A5100617660 |
| ORCID iD | 0000-0002-0593-2662 |
| Works | 297 |

## Researcher papers

- [<i>MET</i> Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib](https://scholariq.org/papers/i-met-i-amplification-identifies-a-small-and-aggressive-subgroup-of/)
- [Adjunctive Systemic Hyperbaric Oxygen Therapy in Treatment of Severe Prevalently Ischemic Diabetic Foot Ulcer: A randomized study](https://scholariq.org/papers/adjunctive-systemic-hyperbaric-oxygen-therapy-in-treatment-of-severe-prevalently/)
- [Bridging Bio–Nano Science and Cancer Nanomedicine](https://scholariq.org/papers/bridging-bio-nano-science-and-cancer-nanomedicine/)
- [TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG](https://scholariq.org/papers/topgear-a-randomized-phase-iii-trial-of-perioperative-ecf-chemotherapy-with-or/)
- [Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers](https://scholariq.org/papers/evaluation-of-combination-nivolumab-and-ipilimumab-immunotherapy-in-patients/)
- [Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy](https://scholariq.org/papers/medium-throughput-drug-screening-of-patient-derived-organoids-from-colorectal/)
- [Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers](https://scholariq.org/papers/immunotherapy-of-ipilimumab-and-nivolumab-in-patients-with-advanced/)
- [TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)](https://scholariq.org/papers/topgear-a-randomised-phase-iii-trial-of-perioperative-ecf-chemotherapy-versus/)
- [Adjuvant Therapy in Gastric Cancer](https://scholariq.org/papers/adjuvant-therapy-in-gastric-cancer/)
- [Part I: Liver function in oncology: biochemistry and beyond](https://scholariq.org/papers/part-i-liver-function-in-oncology-biochemistry-and-beyond/)
- [Early Outcomes of Surgery for Carcinoid Heart Disease](https://scholariq.org/papers/early-outcomes-of-surgery-for-carcinoid-heart-disease/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Neuroendocrine Tumor Research Advances](https://scholariq.org/topics/neuroendocrine-tumor-research-advances/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Colorectal and Anal Carcinomas](https://scholariq.org/topics/colorectal-and-anal-carcinomas/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)

## Researcher university

- [Peter MacCallum Cancer Centre](https://scholariq.org/institutions/peter-maccallum-cancer-centre/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.